Chagas Disease Now Established in California and the Southern United States

Chagas disease, caused by the Trypanosoma cruzi parasite and transmitted by kissing bugs, is now an established health concern in California and the southern United States, with potential underdiagnosis and local transmission.
Chagas disease, traditionally considered a health threat mainly in Latin America, has now been identified as an endemic issue in California and other southern states across the U.S. This insidious disease, caused by the parasite Trypanosoma cruzi, is transmitted through the bites of infected kissing bugs. In the U.S., there are about a dozen kissing bug species, with four known to carry the parasite in California. Notably, in locations like Los Angeles' Griffith Park, up to a third of kissing bugs have been found infected.
The disease remains largely underdiagnosed in the U.S., with estimates suggesting roughly 300,000 individuals may be unknowingly affected. It is often dormant for years, only becoming apparent when it results in severe complications such as heart attacks, strokes, or sudden death. In Latin America, Chagas causes more fatalities annually than malaria, highlighting its deadly potential.
While most U.S. cases are believed to be imported from endemic countries, recent evidence indicates local transmission might also be occurring. Studies show a significant portion of cases reported in California are acquired within the country. However, because Chagas disease is not a reportable illness statewide, its true prevalence remains uncertain. In Los Angeles County alone, between 2019 and 2023, about 18 confirmed cases were identified, though many may go undiagnosed.
The presence of the parasite in local wildlife—including rodents, raccoons, bats, and other animals—along with the widespread distribution of kissing bugs, suggests that the disease could be more prevalent than currently recognized. Experts advocate for the World Health Organization and CDC to declare Chagas disease endemic in the U.S. to increase awareness, surveillance, and public health interventions.
Medical professionals emphasize that early detection and treatment with antiparasitic medications can prevent serious complications, yet many cases remain undiagnosed due to limited screening. The disease's long-term effects include chronic heart and organ damage, which can severely impair quality of life and increase healthcare costs. Dogs are also susceptible, often developing similar cardiac symptoms, and can serve as reservoirs for the parasite.
Public health awareness and proactive screening are essential as the disease continues to emerge within U.S. borders, especially in states with sizable immigrant populations from endemic regions. Addressing the stigma and increasing knowledge about Chagas disease could save lives and reduce the burden of this silent threat.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
How Gut Microbiota Composition Influences the Immune System in Genetically Identical Mice
New research highlights how gut microbiota composition significantly influences immune system structure and function in genetically identical mice, revealing its critical role in immune development and variability.
Study Reveals COVID-19 Pandemic Caused Record Levels of Political Polarization in Vaccine Attitudes
A groundbreaking study reveals that political polarization around COVID-19 vaccine hesitancy was 12 times higher than in past outbreaks, highlighting the profound influence of partisanship on public health responses.
'Obesity Paradox' Extends to Cancer Treatment, New Research Finds
New research suggests that obesity may improve survival rates in cancer patients undergoing immunotherapy, extending the 'obesity paradox' beyond cardiovascular health. Discover the latest findings in this groundbreaking study.
Insurance Status Significantly Influences Survival Rates in Cancer Immunotherapy
Emerging research shows that access to health insurance significantly affects survival rates in cancer patients receiving immunotherapy, emphasizing the need for expanded coverage to reduce disparities in treatment outcomes.